BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte (MXCT)MaxCyteEarnings

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31,

Open original release

Related news

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-02-23 21:05 EST

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

CRBUCaribou2026-03-05 21:05 EST

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SANASana Biotechnology2026-03-03 21:05 EST

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

ABEOAbeona Therapeutics2026-03-03 12:30 EST

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

PASGPassage Bio2026-03-03 12:00 EST

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

SRPTSarepta Therapeutics2026-02-25 21:05 EST

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

KRYSKrystal Biotech2026-02-17 12:00 EST

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

CRSPCRISPR Therapeutics2026-02-12 21:30 EST

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

View all latest news

MaxCyte

MaxCyte is a cell-engineering tools company that provides electroporation platforms used in cell therapy and gene therapy development. Its products support advanced-therapy manufacturing and research workflows.

Recent company news

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-04-29 20:05 EST

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MXCTMaxCyte2026-03-31 20:05 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-03-24 20:05 EST

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MXCTMaxCyte2026-03-23 12:05 EST

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Stock data

Close
1.02 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States